Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Change in Acquisitions & Divestments (2018 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Change in Acquisitions & Divestments for 6 consecutive years, with $87.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Acquisitions & Divestments rose 43216.83% year-over-year to $87.5 million, compared with a TTM value of $178.5 million through Dec 2025, up 614.0%, and an annual FY2025 reading of $178.5 million, up 614.0% over the prior year.
  • Change in Acquisitions & Divestments was $87.5 million for Q4 2025 at Zevra Therapeutics, up from $60.5 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $87.5 million in Q4 2025 and bottomed at $202000.0 in Q4 2024.
  • Average Change in Acquisitions & Divestments over 4 years is $22.9 million, with a median of $13.6 million recorded in 2024.
  • The sharpest move saw Change in Acquisitions & Divestments crashed 98.71% in 2024, then surged 43216.83% in 2025.
  • Year by year, Change in Acquisitions & Divestments stood at $300000.0 in 2022, then surged by 5108.33% to $15.6 million in 2023, then plummeted by 98.71% to $202000.0 in 2024, then soared by 43216.83% to $87.5 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for ZVRA at $87.5 million in Q4 2025, $60.5 million in Q3 2025, and $12.5 million in Q2 2025.